COVID-19 Still Dampens Neurocrine Revenues Despite Industry’s Q3 Uptick
A Pair Of Clinical Holds Hinders The Pipeline
Executive Summary
The pandemic has hit psychiatry offices hard, and the company’s management said it anticipates flat sequential revenues in Q4.